

PROUDLY HOSTED BY



World class cancer care. Close to home.

3rd Annual BREAST CANCER SYMPOSIUM

The Seasons of Breast Cancer

September 24-26, 2021
LIVE Online Event

THIS ACTIVITY HAS BEEN APPROVED FOR

18.5 *AMA PRA
Category 1 Credits™*

ACCREDITED PROVIDER



ACTIVITY PLANNED BY



3rd Annual **BREAST CANCER SYMPOSIUM**

The Seasons of Breast Cancer

PRESENTATION DOWNLOAD

The accredited content presented during the conference will be posted online for viewing and download within 30 days after the conference. An email will be sent to all participants with viewing and download instructions. Not all presentations will be shared due to reprint and permission restrictions.



HOW TO CLAIM CREDIT

- Log in each day on the conference platform.
- You will be emailed instructions for completing the post-test, program evaluation, claiming credit and printing your certificate within 7 days following the conference.



FOR QUESTIONS OR TECHNICAL ASSISTANCE

Email BCS@mymededco.com

Dear Breast Cancer Symposium Attendees:

It is my pleasure to welcome you to New York Oncology Hematology's 3rd Annual Breast Cancer Symposium. We are so excited by the tremendous growth and prominence of this event. Of course, we also look forward to the time when we can come together in person and celebrate the remarkable advances in breast cancer care. Those days are right around the corner!

This conference expresses the passion and compassion of our conference Course Chair and Moderator, Dr. Maria Theodoulou, for the holistic care of women with breast cancer. Ever grounded in science, with rapidly evolving data of translational research trials, and delivered by an esteemed faculty in the breast cancer world.

We thank our event sponsors for their support to bring this conference to you.

Thank you so much for attending and enjoy this engaging time together!

Sincerely,

A handwritten signature in black ink that reads "Todd Doyle". The signature is written in a cursive, flowing style.

Todd Doyle, MD
President, New York Oncology Hematology

Dear Colleagues,

First, I want to thank everyone on behalf of New York Oncology Hematology for supporting the 3rd Annual Breast Cancer Symposium, The Seasons of Breast Cancer, a CME educational program. I am grateful to the faculty for presenting the results of cutting-edge research that guides our treatment of patients with breast cancer. I am grateful to the attendees who want to take this information back to their clinical practices, confirming the excellence of care that they are already performing or adding to that excellence of care. I am grateful for all the grant support received for this symposium which has allowed us to offer this program.

With each season that has passed since the Covid pandemic started and altered our lives globally, the hope was for resolution of the pandemic, as well as successful vaccination in this country and around the world. The hope for each forthcoming season is that we will be able to return to the lives we lived pre-pandemic. With each season we hope for the day that we will be able to come together in a live setting, interacting, sharing information, and building on the hope of tomorrow and for future seasons.


The dedication of scientists, clinicians, and all of the ancillary and supportive services in the oncologic community has continued to move forward in order to achieve the season of success and cure in the breast cancer arena.

This year the faculty enthusiastically agreed to move forward with a web-based program. The agenda is comprised of nationally and internationally known speakers. We will hear about updates that have impacted the clinical pathways available for patients diagnosed with breast cancer in the early setting as well as the advanced setting, novel ways of dissecting an individual patient's breast cancer diagnosis, risk, and how to optimize the patient's survival outcomes.

Although moving forward in our personal lives has slowed, science has gratefully kept on track without delay, continuing to move forward with research from bench to clinic. For three days we will have conversations that will educate and excite us all for when we meet our patients again in our respective clinics the following Monday.

Thank you for being part of this educational event. Thank you for seeing the dream of excellence moving through the seasons of our years, waiting to realize the Spring and Summer of success.

Sincerely,

A handwritten signature in black ink, appearing to read 'M Theodoulou', written in a cursive style.

Maria Theodoulou, MD, Program Chair
New York Oncology Hematology

3rd Annual BREAST CANCER SYMPOSIUM

The Seasons of Breast Cancer

The Conference is being held in Eastern Daylight Time



FRIDAY, SEPTEMBER 24, 2021

8:00 AM - 9:00 AM	Registration & Exhibits	
9:00 AM - 9:30 AM	Non-CME Ancillary Event: Clinical Update on Extended Adjuvant Treatment for HER2+ Breast Cancer	Dr. Vijayakrishna (VK) Gadi (University of Illinois at Chicago Medical Center)
9:30 AM - 10:00 AM	Non-CME Ancillary Event: Combining the HER2+ Breast Cancer Antibodies You Know in One Faster Mode of Administration	Dr. Virginia G. Kaklamani (UT Health)
10:00 AM - 10:15 AM	Introduction	Dr. Maria Theodoulou (NYOH) Dr. Todd Doyle (NYOH)
10:15 AM - 11:15 AM	RADIOLOGY: Breast Cancer Imaging: Current & Future	Dr. Elizabeth Morris (UC Davis)
11:15 AM - 11:50 AM	PATHOLOGY: What Are We Looking For?	Dr. Anna Boguniewicz (AMC)
11:50 AM - 12:35 PM	PATHOLOGY: Special Subtypes	Dr. Edi Brogi (MSKCC)
12:35 PM - 12:45 PM	DISCUSSION AND QUESTIONS	Dr. Maria Theodoulou (NYOH)
12:45 PM - 1:00 PM	Break	
1:00 PM - 1:45 PM	Non-CME Ancillary Event: Clinical Trial Evidence for a CDK4/6 Inhibitor Combination Therapy Complemented by an Evaluation of Real-World Effectiveness	Dr. Sramila Aithal (Alliance Cancer Specialists, P.C.)
1:45 PM - 2:15 PM	Break	
2:15 PM - 2:45 PM	Updates in Hereditary Risk Factors	Dr. Mark Robson (MSKCC)
2:45 PM - 3:15 PM	Management of the High-Risk Patient	Dr. Mary Gemignani (MSKCC)
3:15 PM - 4:00 PM	Metabolic & Energy Balance Perturbations in Breast Cancer Pathogenesis and Treatment	Dr. Neil Iyengar (MSKCC)
4:00 PM - 4:30 PM	Managing Breast Cancer in the Older Patient	Dr. Hyman Muss (UNC)
4:30 PM - 5:30 PM	Molecular Drivers and Advances in the Management of Hormone Receptor Positive HER2neu Negative Early and Advanced Breast Cancer	Dr. Claudine Isaacs (GU)
5:30 PM - 5:50 PM	DISCUSSION AND QUESTIONS	Dr. Maria Theodoulou (NYOH)
5:50 PM - 6:00 PM	DAY 1 - CLOSING REMARKS	Dr. Maria Theodoulou (NYOH)

SATURDAY, SEPTEMBER 25, 2021

8:00 AM - 8:45 AM	Exhibits	
8:45 AM - 9:15 AM	Non-CME Ancillary Event: A CDK 4 & 6 Inhibitor With Overall Survival Data for Women With HR+, HER2- Metastatic Breast Cancer, Including Those Likely To Do Worse	Dr. Peter A. Kaufman (University of Vermont Cancer Center)
9:15 AM - 9:45 AM	Non-CME Ancillary Event: TUKYSA® (tucatinib): Clinical Trial Data	Dr. Lauren Carcas (Miami Cancer Institute)
9:45 AM - 10:00 AM	Break	
10:00 AM - 10:05 AM	WELCOME BACK - DAY 2	Dr. Maria Theodoulou (NYOH)
10:05 AM - 10:50 AM	KEYNOTE LECTURE: The Global Impact of the Pandemic on Oncologic Care	Dr. Clifford A. Hudis, MD, FACP, FASCO (CEO American Society of Clinical Oncology)
10:50 AM - 11:50 AM	Triple-negative Breast Cancer: Early Stage Late Stage	Dr. Tiffany Traina (MSKCC) Dr. Rita Nanda (UoC)
11:50 AM - 12:00 PM	DISCUSSION AND QUESTIONS	Dr. Maria Theodoulou (NYOH)

3rd Annual BREAST CANCER SYMPOSIUM

The Seasons of Breast Cancer

The Conference is being held in Eastern Daylight Time



SATURDAY, SEPTEMBER 25, 2021 (CONTINUED)

12:00 PM - 1:30 PM	Lunch & Exhibits 12:15 PM - 1:15 PM CME SATELLITE: Living Longer with HER2+ Metastatic Breast Cancer <i>Supported by an education grant provided by Seagen, Inc.</i>	
1:30 PM - 2:15 PM	Tailoring Adjuvant Therapy for Early Stage HER2+ Breast Cancer	Dr. Edith Perez (MAYO)
2:15 PM - 3:00 PM	HER2+ Metastatic Breast Cancer	Dr. Chau Dang (MSKCC)
3:00 PM - 4:30 PM	IMMUNOTHERAPY AND BREAST CANCER: THE SCIENCE AND THE PATIENT Moderator: Dr. Stephen Wrzesinski (NYOH)	Dr. George Plitas (MSKCC) Dr. Heather McArthur (UT Southwestern)
4:30 PM - 5:45 PM	RADIATION THERAPY AND BREAST CANCER: Where We Are and Where We're Going Moderator: Dr. Justin Juliano (NYOH) The Evolving Role of Radiation Therapy and Neoadjuvant Systemic Therapy Updates in Who Should Receive and Who Can Avoid Adjuvant Breast Radiation	Dr. Tia Olds (NYOH) Dr. Yasmin Hasan (UoC)
5:45 PM - 5:55 PM	DAY 2 - CLOSING REMARKS	Dr. Maria Theodoulou (NYOH)

SUNDAY, SEPTEMBER 26, 2021

8:00 AM - 9:30 AM	Exhibits	
9:30 AM - 10:00 AM	Non-CME Ancillary Event: Learn More About an FDA-Approved Treatment for Metastatic Triple-Negative Breast Cancer	Dr. Virginia G. Kaklamani (UT Health)
10:00 AM - 10:15 AM	WELCOME BACK - DAY 3	Dr. Maria Theodoulou (NYOH)
10:15 AM - 10:45 AM	Art in Medicine	Dr. Francis Arena (NYU Langone)
10:45 AM - 11:40 AM	ARENA ADVOCACY AWARD & LECTURE: Introduction Lecture: Rethinking Dose and Schedule in Cancer Therapeutics	Dr. Maria Theodoulou (NYOH) Dr. Larry Norton (MSKCC)
11:40 AM - 1:10 PM	Lunch & Exhibits	
1:10 PM - 1:55 PM	De Novo Oligo Metastatic Breast Cancer - Now what? Case Presentation 1 Presentation and Discussion	Dr. Loren Rourke (US Oncology) Dr. Eleftherios Mamounas (UF)
1:55 PM - 2:40 PM	De-Escalation of Local Therapy after Neoadjuvant Chemotherapy — Does that Work? Case Presentation 2 Presentation and Discussion	Dr. Loren Rourke (US Oncology) Dr. Andrea Barrio (MSKCC)
2:40 PM - 3:25 PM	Breast Reconstruction	Dr. Joseph Disa (MSKCC)
3:25 PM - 3:40 PM	BREAK	
3:40 PM - 4:10 PM	BREAST CANCER AND THE LUNG	Dr. Dennis Rassias (SPH)
4:10 PM - 4:40 PM	BREAST CANCER AND THE BRAIN	Dr. Ahmed Meleis (AMC)
4:40 PM - 5:40 PM	METASTATIC BREAST CANCER TO THE BRAIN NonHER2neu HER2neu +	Dr. Andrew Seidman (MSKCC) Dr. Shanu Modi (MSKCC)
5:40 PM - 5:50 PM	DISCUSSION AND QUESTIONS	Dr. Maria Theodoulou (NYOH)
5:50 PM - 6:00 PM	SUNDAY SESSION CLOSE	Dr. Maria Theodoulou (NYOH)

GOAL

Advances in breast cancer health have been growing exponentially during the twenty-first century and the identification of novel therapeutic strategies have led to improved surgical and radiation outcomes. Actionable targets have identified smarter systemic therapies with improved, disease-free, overall survival benefits. In addition to awareness, addressing the health, emotional, and physical well-being of patients after breast cancer treatment has improved the overall quality of life for the patient and their families.

As breast cancer is a multimodal disease, the purpose of this conference is to present the multiple facets that constitute the individual patient's diagnosis, management, and treatment. The goal of this conference is to educate the medical and global community in a forum to foster communication that will benefit the individual patient as well as the community.

TARGET AUDIENCE

Medical, surgical, and radiation oncologists as well as primary care physicians, gynecologists, medical professionals and health care professionals with an interest in breast cancer are invited to attend.

LEARNING OBJECTIVES

After completing this activity, participants will be able to:

- Review the modern surgical approaches addressed in the patient encounter
- Discuss updates in breast cancer imaging for earlier detection
- Identify therapeutic advances in early and advanced hormone receptor-positive, HER2neu overexpressing and triple negative breast cancer
- Review advances in radiation therapy and outcomes
- Identify risk factors and endocrine interventions in patients high risk for developing breast cancer
- Discuss the role of hereditary genetics and the implication to the patient and their families

FEE INFORMATION

The fee for this educational activity is \$400 for physicians (MD/DO), \$100 for advanced practice professionals (NP/PA) and \$50 for all other allied health professionals (RNs/Other).

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the



AT THE FOREFRONT
**UChicago
Medicine**

Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Chicago Pritzker School of Medicine and New York Oncology Hematology, PC, and in collaboration with myMedEd, Inc. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 18.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for *AMA PRA Category 1 Credits™* from organizations accredited by the ACCME, please consult your professional licensing board.

ASSURANCE OF BALANCED, UNBIASED, AND FAIR CONTENT

It is the policy of The University of Chicago Pritzker School of Medicine to ensure balance, independence, objectivity, and scientific rigor in all its individually provided or jointly provided educational activities. Individuals who are in a position to control the content of any educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Mechanisms to ensure that presentations are free from commercial bias are in place. Faculty will also disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentation.

PLANNING COMMITTEE

Maria Theodoulou, MD **(Course Chair & Moderator)**

Program Director
Breast Cancer Medicine
New York Oncology Hematology
Albany, NY

Todd Doyle, MD

President, NYOH
Director of Radiation Therapy
New York Oncology Hematology
Albany, NY

FACULTY

Francis Arena, MD

Director, NYU Langone Arena Oncology
Clinical Professor, NYU Health Medical College
President and Director of Research
Sass Foundation for Medical Research
Lake Success, NY

Andrea V. Barrio, MD, FACS

Associate Attending, Breast Surgical Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Surgery
Weill Cornell Medical College
New York, NY

Anna Boguniewicz MD

Associate Professor
Director, Pathology Residency Training Program
Department of Pathology and Laboratory Medicine
Albany Medical Center
Albany, NY

Edi Brogi MD, PhD

Director of Breast Pathology and
Attending Pathologist
Memorial Sloan Kettering Cancer Center
Professor of Clinical Pathology and
Laboratory Medicine
Weill Cornell Medical College
New York, NY

Chau T. Dang, MD

Medical Director
MSK Westchester Medical Oncology
Attending, Breast Medicine Service
Memorial Sloan Kettering Cancer Center
New York, NY

Joseph J. Disa, MD, FACS

Attending Plastic Surgeon
Vice Chair of Clinical Activities
Department of Surgery
Benno C. Schmidt Chair in Surgical Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Mary L. Gemignani, MD, MPH, FACS

Attending, Breast Service, Department of Surgery
Director, Breast Surgical Fellowship Program
Professor of Surgery
Weill Cornell Medical College
New York, NY

Yasmin Hasan, MD

Associate Professor
Department of Radiation and Cellular Biology
Residency Program Director
Director of Gynecological Brachytherapy
University of Chicago Medical Center
Chicago, IL

Clifford A. Hudis, MD, FACP, FASCO

Chief Executive Officer
American Society of Clinical Oncology
Alexandria, VA

Claudine Isaacs, MD

Professor of Medicine and Oncology
Associate Director, Clinical Research
Leader, Clinical Breast Cancer Program
Georgetown University
Washington, DC

Neil Iyengar, MD

Assistant Attending
Memorial Sloan Kettering Cancer Center
Associate Attending, Rockefeller University
Assistant Professor of Medicine
Weill Cornell Medicine
New York, NY

Justin Juliano, MD

Radiation Oncologist
NYOH Clifton Park
Clifton Park, NY

Eleftherios (Terry) Mamounas, MD, MPH

Medical Director, Comprehensive Breast Program
Orlando Health UF Health Care Center
Professor of Surgery, University of Central Florida
Orlando, FL

Dr. Heather McArthur

Clinical Director of Breast Cancer
Komen Distinguished Chair in Clinical
Breast Cancer Research, UT Southwestern
Dallas, TX

Ahmed Meleis, MD

Assistant Professor of Neurological Surgery
Department of Neurosurgery
Albany Medical Center
Albany, NY

Shanu Modi, MD

Associate Member
Section Head HER2 Breast Program
Memorial Sloan Kettering Cancer Center
Associate Professor, Weill Cornell Medical College
New York, NY

Elizabeth Morris, MD

Chair, Department of Radiology
Professor, Department of Radiology
UC Davis Health
Sacramento, CA

Hyman B. Muss, MD

Mary Jones Hudson Distinguished Professor
of Geriatric Oncology
Professor of Medicine, University of North Carolina
Director of Geriatric Oncology
Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Rita Nanda, MD

Associate Professor of Medicine
Director of Breast Oncology
The University of Chicago
Chicago, IL

Larry Norton, MD, FASCO, FAACR

Senior Vice President, Office of the President
Medical Director, Evelyn H. Lauder Breast Center

Deputy Director for Clinical and Translational
Science, MSK Comprehensive Cancer Center
Norna S. Sarofim Chair of Clinical Oncology
New York, NY

Tia Olds, MD

Radiation Oncologist
New York Oncology Hematology
Albany, NY

Edith A. Perez, MD

Professor of Medicine
Director, Breast Cancer Translational
Genomics Program
Mayo Clinic
Jacksonville, FL

George Plitas, MD

Associate Attending, Breast Service
Department of Surgery
Memorial Sloan Kettering Cancer Center
New York, NY

Dennis J. Rassias, MD, FACS

Chief of Thoracic Surgery
St. Peter's Health Partners
Albany, NY

Mark E. Robson, MD

Chief, Breast Medicine Service
Attending Physician, Breast Medicine
and Clinical Genetics Services
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

Loren L. Rourke, MD, MHCM, FACS

Chief Surgical Officer, US Oncology Network
The Woodlands, TX

Andrew Seidman, MD

Medical Director, Bobst International Center
Attending Physician, Breast Medicine Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

Tiffany A. Traina, MD

Vice Chair, Oncology Care
Department of Medicine
Associate Attending Physician
Section Head, Triple Negative Breast Cancer
Clinical Research Program
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medicine
New York, NY

Stephen H. Wrzesinski MD, PhD

Director of Immunooncology and Cellular Therapy
Medical Oncologist
New York Oncology Hematology
Clinical Assistant Professor of Medicine
Albany Medical College
Albany, NY

PLANNING COMMITTEE BIOGRAPHIES



Maria Theodoulou, MD (Course Chair & Moderator)

Dr. Maria Theodoulou is recognized nationally and internationally for her breast cancer clinical research. Prior to joining New York Oncology Hematology, Dr. Theodoulou was an attending physician at Memorial Sloan-Kettering Cancer Center and Professor of Medicine at the Joan and Sanford Weill Medical College of Cornell University, both in New York City. Dr. Theodoulou is board certified in internal medicine as well as medical oncology.

Dr. Theodoulou's passion for clinical research is patient-driven, constantly searching for individualized therapy with minimal toxicities. She is a recipient of multiple prestigious awards including Leading Physicians of the World Top Breast Medical Oncologist in New York City 2019 and 2020, the Hally Yaccino Steiner Award–Susan G. Komen for the Cure Greater New York City, Lifetime Achievement Award Cyprus Federation of America, Irka Wozniak Memorial Lecture Award Sass Foundation for Medical Research, Commendation Office of Comptroller City of New York, Outstanding Physician Award Sass Foundation for Medical Research, Hellenic Medical Society Kalopothakes Distinguished Female Physician Award, ASCO Merit Award.

Dr. Theodoulou is presently the Program Director Breast Cancer Medicine at New York Oncology Hematology, the organizer and host/moderator of the NYOH Breast Cancer Symposium 2019, 2020, 2021, a nationally and internationally recognized CME educational program, as well as the host of the Fireside Virtual Chat Panel for Breast Cancer Survivorship Education for Patients and their family and friends.



Todd Doyle, MD

Dr. Doyle was trained as a radiation oncologist at the Mallinckrodt Institute of Radiology and the Hospital of the University of Pennsylvania. He is currently the president and director of radiation oncology at New York Oncology Hematology PC. He is a Susan G. Komen Honoree for the treatment of breast cancer and has published on the treatment of breast cancer in the International Journal of Radiation Oncology Biology and Physics. He has served as a written and oral examiner for the American Board of Radiology as well as on numerous other academic and administrative committees. Current interests include novel modalities in the delivery of radiation therapy including SRS and SBRT in addition to the treatment of breast cancer.

FACULTY BIOGRAPHIES



Francis Arena, MD

Francis P. Arena, MD, FACP is the director of one of New York's largest oncology practice groups, The NYU Langone Arena Oncology Center, located in Lake Success, NY. He is also a Clinical Associate Professor of Medicine at New York University and Adjunct Clinical Assistant Professor of Medicine at Cornell University Medical College.

Dr. Arena received his Bachelor of Science Degree from Fordham University and his Medical Degree from Cornell University Medical College. His internship and residency were carried out at New York Hospital/Memorial Hospital, after which Dr. Arena served as Chief Medical Resident and later as Hematology/Oncology Fellow at the Memorial Sloan-Kettering Cancer Center. He is Board Certified in Internal Medicine and Medical Oncology.

Because of his keen interest in cancer research and preventative cancer care, Dr. Arena helped establish and is the president of the SASS Foundation for Medical Research, which supports medical fellows at a number of hospitals. He is on the Advisory Board of "1 in 9", the Breast Cancer Coalition, and serves as a consultant for numerous pharmaceutical companies. Dr. Arena is widely published and has lectured extensively in his field. He is an Assistant Editor of the journal *Oncology* and previously on the Editorial Board of the *Community Oncology* journal. Dr. Arena has been the recipient of multiple awards and citations for his work in oncology and breast cancer. Some of these awards include the David award

continued →

given by *Networking* magazine, The Eileen Dryer Award by the Sass Foundation, the Il Leone de San Marco award in medicine by the Italian-American League of Westchester and the Bronx and has been cited in repeated years as one of the top oncologists in the New York Metropolitan area by the *Castle Connely* magazines and *Newsday*. Frank lives with his wife and wonderful children in Long Island, NY.

Dr. Arena was the co-producer of the Bermuda Pink Conference On Breast Cancer and was solely responsible for assembling the expert panel of doctors from NYU Langone, Weill Cornell, Sloan Kettering, North Shore LIJ and Harvard Medical. He received the prestigious Bermuda International Citizenship Award for his moderating and production of the conference.



Andrea V. Barrio, MD, FACS

Andrea V. Barrio, MD, FACS is an Associate Attending with the Breast Service, Department of Surgery at Memorial Sloan Kettering Cancer Center, and an Associate Professor of Surgery at Weill Cornell Medical College. Dr. Barrio received her BS degree from the University of California, Los Angeles and her MD from the University of California, Los Angeles School of Medicine, where she was elected to the membership of the Alpha Omega Alpha Honor Medical Society. She completed her surgical residency at New York Presbyterian Hospital, Weill Cornell Medical Center, followed by one year of breast surgical oncology fellowship training at Memorial Sloan Kettering Cancer Center.



Anna Boguniewicz MD

Dr. Anna Boguniewicz is an Associate Professor of Pathology, Director of Cytology and the Director of Residency Training in Pathology and Laboratory Medicine at Albany Medical Center, Albany New York. She has served as the pathologist for the interdisciplinary breast tumor conference and the primary liaison for the breast oncologists, surgeons and radiologists for many years at AMC. She has also been active in teaching breast pathology to medical students, residents and other allied health care professionals.



Edi Brogi MD, PhD

Edi Brogi MD, PhD is an Attending Pathologist and the Director of Breast Pathology at Memorial Sloan Kettering Cancer Center. Dr. Brogi is a graduate of the University of Florence Medical School, in Florence, Italy. She trained in Anatomic Pathology at the Massachusetts General Hospital in Boston, followed by two additional years as Chief Resident/Graduate Assistant and Cytopathology fellow at the same institution. In July 2000, Dr. Brogi joined the staff at Memorial Sloan Kettering Cancer Center in New York City, NY and has been practicing there ever since.

Dr. Brogi's professional and research activities focus exclusively on the diagnosis, treatment, and study of breast diseases, particularly breast carcinoma. She is recognized as an expert in the field nationally and internationally.

Throughout her career Dr. Brogi has been actively involved in education and teaching. She has trained over 40 breast pathology fellows and mentored junior breast pathologists, including few up-and-coming leaders in the field.

Dr. Brogi was a member of the United States and Canadian Academy of Pathology (USCAP) Education Committee (2012-2016) and co-directed the USCAP Long Course in Breast Pathology in March 2020. She is a member of the USCAP Board of Directors (2020-2023).

Dr. Brogi was Officer of the International Society of Breast Pathology in 2012-2016, and President of the Society in 2017-2019. Dr. Brogi has published over 200 original articles, review articles, and book chapters, predominantly focused on breast diseases. She is Associate Editor of *Rosen's Breast Pathology* by needle core biopsy textbook (4th edition, 2017) and *Rosen's Breast Pathology* textbook (4th edition, 2014 and 5th edition 2020).

Dr. Brogi is an expert member of the Editorial Board of the World Health Organization *Blue Book on the Classification of Breast Tumors* (5th Edition).



Chau T. Dang, MD

With an interest in evaluating combination therapies that include anti-HER2 drugs with chemotherapy in the treatment of patients with early-stage and metastatic HER2-positive breast cancer, Dr. Dang focuses on developing more effective and less toxic treatment strategies for women with this disease. Her research and an investigator-initiated trial at Memorial Sloan Kettering has led to the widespread use and National Comprehensive Cancer Network (NCCN) endorsement of a dose-dense, anthracycline/taxane-containing chemotherapy regimen followed by trastuzumab in patients with early-stage HER2-positive breast cancer. A second investigator-initiated study that evaluated dual anti-HER therapy with trastuzumab and pertuzumab and chemotherapy for patients with HER2-positive metastatic breast cancer led to the NCCN endorsement of this regimen as a standard option in treating patients with metastatic HER2-positive breast cancer. A third investigator-initiated study on dual anti-HER2 therapy with trastuzumab and lapatinib with chemotherapy also had an impact on research worldwide. Dr. Dang and her colleagues are currently leading other research trials, both locally and internationally that focus on the unique cardiac toxicities of anthracyclines and anti-HER2 agents. To allow for improved patient selection and monitoring, she studies cardiac biomarkers, with a future goal of facilitating early interventions to minimize acute and late cardiac effects of cancer treatment.

Dr. Dang is board-certified in internal medicine and medical oncology with clinical expertise in breast cancer. She received her MD at the Medical University of South Carolina followed by Internal Medicine Residencies at Allegheny General Hospital/Medical College of Pennsylvania and Fellowships in Hematology/Oncology at Memorial Sloan Kettering Cancer Center.



Mary L. Gemignani, MD, MPH, FACS

Mary L. Gemignani, MD, MPH, FACS is a surgeon who specializes in the diagnosis and treatment of breast cancer. She joined Memorial Sloan Kettering in 1996 and completed fellowships in both breast surgery and gynecologic oncology and has been practicing at MSK ever since. Dr. Gemignani's dual training, research interests, and experience make her uniquely suited to provide expert care for women with hereditary breast cancer. This includes doing risk-reducing double mastectomies for women with BRCA mutations or other familial risks.

Dr. Gemignani performs about 300 procedures each year and sees patients at MSK's Breast and Imaging Center in Manhattan. Her goal is not only to provide advanced surgical techniques, but also to bring together a team of superb colleagues in medical oncology, radiation oncology, and plastic surgery who then make a comprehensive treatment plan tailored to each patient.

From early on in medical school, Dr. Gemignani knew that she wanted to dedicate her career to women's health and oncology. She provides care that takes into account quality of life concerns for women with breast cancer, including cosmetic outcomes. When appropriate, Dr. Gemignani offers cosmetic options such as nipple-sparing mastectomy and aims to minimize the side effects of breast cancer surgery. It's her goal to help patients get back to their lives as quickly as possible after surgery.

Dr. Gemignani's current research interest is in patient-reported outcomes, which involves studying symptoms and side effects after surgery directly from the patient's perspective. This information is vital for finding ways to improve the surgical experience for patients. She is also studying how best to address the fertility concerns of young women who have been diagnosed with breast cancer.

Dr. Gemignani is the Director of MSK's Breast Surgical Fellowship Training Program and is responsible for the educational training program for a highly selected group of surgeons choosing to specialize in breast surgery. She is an active member of local, national, and international societies. These include the American College of Surgeons, the Society of Surgical Oncology, the American Society of Breast Surgeons, and the American Society of Clinical Oncology.

As a surgeon, Dr. Gemignani aims to provide hope and support as women with cancer navigate one of the most difficult times in their lives. At the end of a consultation, she wants each of her patients to feel that they have the information they need to make decisions about their treatment. She wants them to have less fear about their diagnosis and to know that she will be with them to help and guide them through their journey.

Outside of work, Dr. Gemignani is an avid runner, and enjoys spending time with her family.



Yasmin Hasan, MD

Yasmin Hasan, MD, Associate Professor of Radiation Oncology, specializes in the treatment of breast and gynecologic cancers. She uses highly targeted, localized radiation techniques – such as brachytherapy and intensity-modulated radiotherapy (IMRT) – to minimize damage to the healthy tissue surrounding a malignancy. Dr. Hasan's research focuses on finding patterns in breast cancer and gynecologic cancer outcomes, with the goal of developing preventative therapies and improving definitive treatment. An accomplished author, Dr. Hasan has published several articles in peer-reviewed journals and contributed to book chapters on the role of external beam radiation in the management of malignant diseases.



Clifford A. Hudis, MD, FACP, FASCO

Dr. Hudis is the Chief Executive Officer of the American Society of Clinical Oncology (ASCO). He also serves as the Executive Vice Chair of its Conquer Cancer Foundation and Chair of ASCO's CancerLinQ. Dr. Hudis previously served in a variety of volunteer and leadership roles at ASCO, including as its President during the Society's 50th anniversary year (2013-14). Before coming to ASCO full-time, he was the Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Professor of Medicine at the Weill Medical College of Cornell University. As CEO of ASCO, Dr. Hudis is responsible for delivering on the board's strategic goals through education, research, and support for the delivery of the highest quality, equitable care by the Society's nearly 45,000 members.



Claudine Isaacs, MD


Dr. Claudine Isaacs is a Professor of Medicine and Oncology, Associate Director of Clinical Research, and Leader of the Breast Disease Group at the Lombardi Comprehensive Cancer Center (LCCC) at Georgetown University. She is also the Medical Director of the Jess and Mildred Fisher Center for Hereditary Cancer and Clinical Genomics Research. She has extensive experience in the conduct of clinical trials focusing on all aspects of breast cancer and currently serves as Co-Chair Endocrine Resistance Working Group of the Translational Breast Cancer Research Consortium (TBCRC) and as Co-Chair of the Clinical Trials Operations Working Group for the I-SPY 2 Trial. She has authored over 200 peer-reviewed publications and edited two textbooks. She has served on a number of national committees including the Cancer Education and the Scientific Program Committees at ASCO, the Breast Oncology Local Diseases Task Force of the Breast Steering Committee of the NCI, and the ASCO Breast Cancer Guideline Advisory Group.



Neil Iyengar, MD

Dr. Neil Iyengar is a board certified Medical Oncologist and clinical-translational researcher at Memorial Sloan Kettering Cancer Center (MSKCC) where he specializes in the care of patients with breast cancer. He also holds joint research appointments at the Rockefeller University Center for Clinical and Translational Science and Weill Cornell Medicine in New York. Dr. Iyengar received his undergraduate and medical degrees from the University of Illinois at Chicago accelerated degree program where he graduated with the College's highest honors (University Scholar). He completed residency training in Internal Medicine at the University of Chicago Medical Center followed by fellowship in medical oncology and hematology at MSKCC. He now holds a faculty position as an Associate Attending on the Breast Medicine Service at MSKCC.

Dr. Iyengar's research program investigates interventions to improve metabolic health as a strategy to reduce breast cancer risk and mortality. His group is testing the anti-cancer effects of structured exercise and nutritional interventions in people at high risk or diagnosed with breast cancer. Dr. Iyengar's research is also investigating the use of drugs that treat metabolic disorders, such as diabetes and obesity, to improve the effectiveness of cancer therapies. In an effort to rapidly translate this work, Dr. Iyengar also leads the Optimal Living Program, a novel cancer care model that aims to translate research findings from lifestyle intervention trials into clinical practice during and after cancer therapy. His work has been recognized and awarded by several organizations, including research grants from the National Cancer Institute, American Cancer Society, the Breast Cancer Research Foundation, Conquer Cancer the ASCO Foundation, and others. He has published numerous original research articles and has been an invited speaker at several international conferences.



Justin Juliano, MD

Dr. Juliano is a native of the Capital District and was born in Saratoga Springs, NY. He completed his medical training at SUNY Upstate Medical Center in Syracuse, NY, in 2002. He subsequently completed radiation oncology residency training at Cleveland Clinic in June 2007. Dr. Juliano joined the Cleveland Clinic staff pursuing his interest in gynecologic cancer as well as high dose rate brachytherapy for a wide range of malignancies. Additionally, he developed the clinical hyperthermia program for both superficial and interstitial applications. Dr. Juliano joined Penn State Hershey Medical Center in April 2010 continuing his interest in high dose rate brachytherapy and gynecologic malignancy, and expanded his service to genitourinary malignancy. While there, he developed a permanent prostate implant program. In January 2015, Dr. Juliano returned to the Capital District and joined New York Oncology Hematology. Dr. Juliano maintains a diversified clinical interest and remains engaged in clinical research. In his spare time, Dr. Juliano enjoys spending time with his wife and four children as well as skiing and hiking.



Eleftherios (Terry) Mamounas, MD, MPH

Terry P. Mamounas, MD, is Medical Director of the Comprehensive Breast Program at Orlando Health UF Health Cancer Center, Professor of Surgery at University of Central Florida and Clinical Professor of Clinical Sciences at Florida State University. He is past Chair of the NSABP Breast Committee and current Chair of the NRG Oncology Breast Committee.

Dr. Mamounas received his medical degree from the University of Athens Medical School in Athens, Greece, and a Masters of Public Health degree in Epidemiology from the University of Pittsburgh. He completed his surgical residency at McKeesport Hospital in McKeesport, Pennsylvania, an oncology research fellowship at the University of Pittsburgh and a surgical oncology fellowship at Roswell Park Cancer Institute in Buffalo, New York.

Dr. Mamounas has authored or co-authored over 400 abstracts, manuscripts, and book chapters, and he has given numerous presentations on breast cancer at various regional, national, and international symposia. His clinical research has focused on the surgical and adjuvant treatment of early-stage breast cancer. He is a member of several professional societies including the American College of Surgeons, the Society of Surgical Oncology, the American Society of Clinical Oncology and the American Society of Breast Surgeons. Dr. Mamounas is a member of the NCI Breast Cancer Steering Committee. He serves on several editorial boards and he is past associate editor for the *Journal of Clinical Oncology*. Dr. Mamounas is a past member of the Scientific Advisory Council for the Susan G. Komen for the Cure.



Dr. Heather McArthur

Heather McArthur, MD, MPH is the Clinical Director of Breast Cancer at University of Texas Southwestern Medical Center (UTSW) and Komen Distinguished Chair in Clinical Breast Research. Dr. McArthur is a medical oncologist with a clinical practice dedicated to the care of patients with breast cancer. Her research activities are focused on innovations in the diagnosis and treatment of breast cancer, with a particular interest in novel immune therapy strategies. For example, she is currently evaluating the impact of tumor destruction with freezing (cryoablation) or radiation in combination with immune stimulation for the treatment of women with early-stage breast cancer. It is hoped that by augmenting one's immune response to the unique biologic features of one's tumor, that an affected individual may develop long-term immunity against their tumor, and thus, be cured.

Dr. McArthur completed formal medical oncology training in Canada where she was awarded a highly competitive grant that funded an advanced fellowship at Memorial Sloan Kettering Cancer Center (MSKCC) in New York. Thereafter, she joined MSKCC as faculty where she developed the institutional breast cancer immunotherapy program before joining CSMC in 2016 and UTSW in 2021. She has a Master's in Public Health with a focus on clinical trial design from Harvard University and has mentored many medical students, residents, fellows, and junior faculty in the conduct and reporting of several studies - two of which directly informed National Comprehensive Cancer Network treatment guidelines.

Dr. McArthur has held several leadership positions in the field including Co-Chair of a Breast International Group Immunotherapy Taskforce, member of a National Cancer Institute (NCI) Breast Cancer Immunotherapy (IO) Working Group, member of the NCI Breast Cancer IO Task Force, and member of an Alliance for Clinical Trials in Oncology IO Committee. She has served the American Society of Clinical

continued →

Oncology (ASCO) on the Annual Meeting IO Scientific Committee, the YIA/CDA Grant Selection Committee, the Breast Cancer Symposium Program Committee, the Annual Meeting Grant Writing Workshop, a Guideline Expert Panel, and Educational Book Expert Panels. She has participated in the ASCO Leadership Development Program; reviewed manuscripts for various high-impact journals; authored numerous articles; and served on many study steering committees. She has designed, conducted, and reported on many studies in breast cancer and is currently the co-PI for a large, randomized, international phase 3 study exploring adjuvant chemotherapy with or without immune therapy for the treatment of triple-negative breast cancer (IMpassion030).



Ahmed Meleis, MD

Ahmed M. Meleis, MD is one of the region's few fellowship-trained neurosurgical oncologists in the greater Capital Region.

Dr. Meleis brings advanced surgical treatment of primary and metastatic tumors of the spine and brain. A New Jersey native, Dr. Meleis completed his undergraduate studies at Princeton University and then went on to earn his medical degree at Rutgers University. He then stayed on at Rutgers and completed his neurosurgery training. After completion of residency, he went on to do his fellowship training in Neurosurgical Oncology at the prestigious University of Texas MD Anderson Cancer Center in Houston, Texas. His research interests focus on the outcomes of surgery and radiation treatment for spinal tumors.



Shanu Modi, MD

Shanu Modi, MD, is an associate member of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City. She received her medical degree from the University of Alberta in Edmonton, Canada where she also completed a residency in internal medicine. She followed this with subspecialty training in medical oncology at the Cross Cancer Institute and subsequently completed a 4-year fellowship in Breast Cancer Research at MSKCC. She has been a full-time faculty member on the Breast Medicine Service at MSKCC since 2005.

Dr. Modi has been chair and member of the Scientific Program Committee for HER2 Positive Breast Cancer from 2013-2016 and a member of the grant selection committee for the American Society of Clinical Oncology (ASCO) from 2013 to 2015. She received the Conquer Cancer Foundation Advanced Clinical Research Award in 2009 for her work in Heat Shock Protein Inhibition. And was awarded and held the Patricia and James Cayne Chair for Junior Faculty at MSKCC from 2009-2012.

She also has a significant clinical research program in the development of HER2 targeted therapies and is currently the Section Head for the HER2 Breast Cancer Program on the Breast Medicine Service at MSKCC. She is also a member of the Expert Committee to establish Guidelines for Patients with Advanced HER2+ Breast Cancer, where she serves on the Breast Cancer Consensus Panel. She is also a member of the Scientific Committee for the European Society of Medical Oncology (ESMO) as part of the metastatic breast cancer track responsible for abstract selection.

She is an ad hoc reviewer for the *Journal of Clinical Oncology*, *Clinical Breast Cancer*, *Breast Cancer Research and Treatment*, and the *Journal of Surgical Oncology*. She has authored or co-authored more than 50 peer-reviewed articles as well as books, book chapters, and reviews.

Dr. Modi holds memberships in ASCO, ESMO, the American Association for Cancer Research, ALLIANCE for Clinical Trials in Oncology, and the Translational Breast Cancer Consortium. She has been an invited speaker for national and international congresses, meetings, and symposiums.



Elizabeth Morris, MD

Elizabeth Morris, MD is Professor and Chair of Radiology at the University of California, Davis (UCD) School of Medicine. Dr. Morris graduated summa cum laude from UCD in Biochemistry and received her medical degree from the University of California, San Francisco (UCSF). She completed her residency at Weill Cornell Medical College (WCMC) and a body/breast imaging fellowship at Memorial Sloan Kettering Cancer Center (MSKCC) where she remained on faculty until December 2020 where she was the Chief of the Breast Imaging Service and Larry Norton Endowed Chair.

Dr. Morris is a fellow of the American College of Radiology (ACR), Society of Breast Imaging (SBI) and International Society of MR in Medicine (ISMRM) and is past president of the SBI. She is the inaugural Equity Diversity & Inclusion officer of the ISMRM and co-chair of the Women of ISMRM (WISMRM).

Her research focus is on how best to use newer techniques such as MRI for early breast cancer detection and to improve the workup of breast lesions. In collaboration with her colleagues, she has written over 230 papers, 40 chapters, and 5 books about breast disease with an emphasis on the use of MRI. She lectures widely both nationally and internationally at over 320 conferences. She has mentored over 50 international research fellows. She has grants from NCI, RSNA, Komen Foundation, and Breast Cancer Research Foundation. She has authored a book "Breast MRI: Diagnosis & Intervention". Her recent research efforts have involved looking at imaging biomarkers to assess risk and treatment response.



Hyman B. Muss, MD

Hyman B. Muss MD is an experienced clinician-scientist, the Mary Jones Hudson Distinguished Professor of Geriatric Oncology at the University of North Carolina School of Medicine, and the Director of the Geriatric Oncology Program at the UNC Lineberger Comprehensive Cancer Center Program. His interest is education and research focused on cancer in older patients and is an internationally recognized leader in this area. His particular interest and research expertise is in the care of breast cancer patients with a focus on the management of older women. He also has a major interest in breast cancer survivorship and long-term toxicity of treatment. After working with his previous UNC colleague, Dr. Ned Sharpless, he is exploring the role of biomarkers of aging and their potential role as predictors of toxicity and survival. Dr. Muss has developed and been PI of multiple clinical and translational trials including lead author of an NCI-sponsored intergroup trial that compared standard care with oral chemotherapy in older women with early stage breast cancer and which for the first time showed the value of chemotherapy in this older populations. He serves as the mentor for medical students, medicine residents, junior faculty, and more recently Geriatric Oncology fellows. He previously co-chaired the Alliance Committee on Cancer in Older Adults. He has been co-chair of the Breast Committee for the CALGB, Chair and a member of the board of Directors of the American Board of Internal Medicine, and a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and the ASCO Foundation. He was awarded the B.J. Kennedy Award in Geriatric Oncology by ASCO, the Susan G. Komen for the Cure Brinker Award for Scientific Distinction in Clinical Research, and an honorary Doctor of Science Degree from his alma mater, Lafayette College. He has served in the U.S. Army in Vietnam where he was awarded the Bronze Star medal.



Rita Nanda, MD

Rita Nanda, MD, is an Associate Professor of Medicine and Director of Breast Oncology at The University of Chicago. Dr. Nanda earned her undergraduate degree in Chemical Engineering from the Massachusetts Institute of Technology, and her Medical Degree from The University of Chicago, Pritzker School of Medicine. She subsequently completed her Residency in Internal Medicine and her Fellowship in Hematology/Oncology at The University of Chicago.

Dr. Nanda's research interests include identifying novel treatments for the management of breast cancer, particularly triple-negative disease. Dr. Nanda has authored numerous scientific publications and book chapters, including one of the first reports of immune checkpoint inhibitor therapy for triple-negative breast cancer.

She is a member of the Breast Immuno-Oncology (BIO) Taskforce of the National Cancer Institute (NCI) Breast Cancer Steering Committee (BCSC), and serves as a Principal Investigator for the Translational

continued →

Breast Cancer Research Consortium (TBCRC) and the ISPY2 Clinical Trial Network. She is a member of the American Society of Clinical Oncology, the American Association of Cancer Research, and the Society for Immunotherapy of Cancer.

Dr. Nanda's research has been funded by The NIH, The Department of Defense Breast Cancer Research Program, The Doris Duke Charitable Foundation, The Susan G. Komen Foundation, The Metastatic Breast Cancer Network, and the Breast Cancer Research Foundation. She was awarded the 2014 NCI Cancer Clinical Investigator Team Leadership Award, and currently serves as the co-PI for the University of Chicago Interdisciplinary Cancer Health Disparities SPORE.



Larry Norton, MD, FASCO, FAACR

Larry Norton, MD is the Norna S. Sarofim Chair of Clinical Oncology, Senior Vice President in the Office of the President, and Deputy Director for Clinical and Translational Science in the Memorial Sloan Kettering Cancer Center, New York. He is also the Medical Director of the Evelyn H. Lauder Breast Center at MSK and is a founder of the Breast Cancer Research Foundation, serving as Scientific Director and then Founding Scientific Director since the foundation's inception in 1993. Dr. Norton has served on or chaired numerous committees of the National Cancer Institute, National Institutes of Health, and the Institute of Medicine of the National Academy of Sciences and has served as President of the American Society of Clinical Oncology among other leadership roles in that and other organizations. He is also a Fellow of the American Society of Clinical Oncology and of the American Association for Cancer Research Academy.

Dr. Norton has dedicated his life to the eradication of cancer by activities in medical care, laboratory and clinical research, advocacy and government. His research is broad, but he is best known for mathematical modeling in therapeutic development. He has been involved in the development of several effective agents including paclitaxel and trastuzumab. He co-invented the Norton-Simon Model of cancer growth which has broadly influenced cancer therapy, and more recently the self-seeding concept of cancer metastasis and growth. He is the Principal Investigator of the BCRF-Simons Mathematical Oncology Initiative and an author of more than 400 published articles and many book chapters.

Among many honors, he received ASCO's Karnofsky and Bonadonna Awards, the McGuire Lectureship at the San Antonio Breast Cancer Symposium, MSKCC's Whitmore Award for Clinical Excellence, the Columbia University's Gold Medal for Outstanding Achievement in Medical Research, The Cold Spring Harbor Laboratory Double Helix Award as well as the Thomson Reuters Highly Cited Researcher Certificate.



Tia Olds, MD

Tia D. Olds, MD, is a radiation oncologist at New York Oncology Hematology, a practice in The US Oncology Network, in Albany, NY. She earned her medical degree from Morehouse School of Medicine in Atlanta, interning at Saint Vincent's Medical Center in Staten Island, NY, and serving her residency in radiation oncology at SUNY Upstate Medical Center in Syracuse, NY.

A member of the American Society of Therapeutic Radiology and Oncology, Dr. Olds has earned multiple honors and awards, including the Morehouse School of Medicine Academic Achievement Award, the Janet Glasgow National Academic Citation, the Morehouse School of Medicine Award for Laudable Achievement in Internal Medicine, and recognition from the Alpha Omega Alpha Medical Honor Society.



Edith A. Perez, MD


Edith A. Perez, MD, is the Serene M. and Frances C. Durling Professor of Medicine at Mayo Clinic College of Medicine. Dr. Perez is a cancer specialist and an internationally known translational researcher. Her roles extended nationally, including group vice chair of the Alliance for Clinical Trials in Oncology and other positions within the American Association for Cancer Research, the American Society of Clinical Oncology and the National Cancer Institute.

Dr. Perez has authored more than 700 research articles in journals, books and abstracts and is invited frequently to lecture at national and international meetings. Dr. Perez serves on the editorial boards of multiple academic journals.



George Plitas, MD

Dr. Plitas is an Associate Attending Surgical Oncologist at the Memorial Sloan Kettering Cancer Center who specializes in the treatment of patients with breast cancer. He obtained his M.D. and general surgical training from the New York University Medical Center. He has also completed the Surgical Oncology Fellowship at MSKCC. Dr. Plitas holds the Jeanne A. Petrek Junior Faculty Chair and conducts translational immunology focused on determining how the tumor microenvironment shapes the phenotype and function of tumor resident immune cells.



Dennis J. Rassias, MD, FACS

Dennis J. Rassias, MD, FACS completed his general surgery training in Stamford Hospital in Connecticut in 2003. He then completed cardiothoracic surgery training at Albany Medical Center in Albany, New York in 2005. From 2005 until 2007, Dr. Rassias worked in private practice in both general and thoracic surgery in Massachusetts. During that time his interest shifted simply to thoracic surgery.

In 2007, Dr. Rassias completed a three-month super-fellowship in minimally invasive thoracic surgery. He returned to Albany at St. Peter's Hospital to practice thoracic surgery and joined Dr. Darroch Moores who is a very well-known thoracic surgeon. Together, they co-authored a book chapter on transhiatal esophagectomy in 2014.

Dr. Rassias has been the Chief of Thoracic Surgery at St. Peter's Hospital since 2011. His interests lie in thoracic oncology (lung and esophagus) and minimally invasive thoracic surgery.



Mark E. Robson, MD

Dr. Robson graduated from the University of Virginia School of Medicine in Charlottesville, Virginia, and did his internal medicine residency and hematology-oncology fellowship training at Walter Reed Army Medical Center in Washington DC. He is currently Chief of the Breast Medicine Service in the Department of Medicine at Memorial Hospital in New York, Attending Physician on Breast Medicine and Clinical Genetics Services, and a Member of the Memorial Sloan Kettering Cancer Center. His clinical research has concentrated on the optimal application of germline information to the management of cancer patients, particularly those with breast cancer. He has been a lead investigator for a number of trials of PARP inhibitors in patients with BRCA mutation-associated breast cancer. In addition to studying PARP inhibition as a therapeutic strategy, he is currently developing new models for the acquisition of germline information, including "mainstreaming" through test ordering by primary oncology providers and broad genomic screening in the context of somatic mutational profiling. He is also investigating the use of polygenic risk scores in facilitating decision-making among women with or without an inherited predisposition. He is an associate editor for the Journal of the National Cancer Institute. He is a Fellow of the American Society of Clinical Oncology, past Chair of the Ethics Committee of that organization and has served several terms on the ASCO Cancer Prevention Committee and its Cancer Genetics subcommittee.



Loren L. Rourke, MD, MHCM, FACS

Originally from the Northeast, Dr. Loren Rourke is a fellowship-trained breast surgical oncologist with extensive experience building comprehensive multidisciplinary breast programs in community, academic, and hybrid environments. She has dedicated her career to ensuring patients receive exceptional care in a compassionate and informative atmosphere. She completed her general surgery residency at the University of Tennessee in Knoxville, the Susan G. Komen Interdisciplinary Breast Fellowship at UT MD Anderson Cancer Center, and most recently a Master's in Healthcare Management from the Harvard T.C. Chan School of Public Health as part of her pursuit to broaden her business understanding of the current healthcare landscape. She currently serves as the first-ever Chief Surgical Officer for McKesson's US Oncology Network, a role dedicated to the improvement and strategic development of surgical services across the Network.



Andrew Seidman, MD

Dr. Andrew Seidman is the Medical Director, Bobst International Center, Professor of Medicine at Weill Cornell Medical College, an Attending Physician for the Breast Medicine Service at Memorial Sloan Kettering Cancer Center in New York City.

Dr. Seidman earned his medical degree from Hahnemann University School of Medicine in Philadelphia, Pennsylvania. He completed a residency in Internal Medicine at The Pennsylvania Hospital. Dr. Seidman then completed a fellowship in Medical Oncology and Hematology at Memorial Sloan Kettering Cancer Center in New York.

Dr. Seidman has authored or co-authored more than 200 peer-reviewed articles, reviews and book chapters, as well as over 150 abstracts, and he has served on the editorial boards of over a dozen leading journals. He has led pivotal clinical trials that inform the current use of paclitaxel and trastuzumab, amongst other agents, in the management of breast cancer. He has presented at innumerable national and international conferences and symposia on breast cancer related topics. He is currently a Principal Investigator on several clinical trials. Dr. Seidman has served as President of the American Society of Breast Disease, has received the Gay Clark Stoddard Award from the Susan G. Komen Foundation “in recognition of his compassion and commitment to the field breast health care and research”, and the Jacob Ehrenzeller Award for Academic Excellence. He is the recipient of a Career Development Award from ASCO, and has served on the ASCO Communications Committee. Dr. Seidman currently serves as Associate Chair, Academic Administration at MSKCC, and has an active research program focused on breast cancer brain metastases, and computer-assisted decision support in oncology, working with the MSK-IBM-Watson Team.



Tiffany A. Traina, MD

Dr. Tiffany A. Traina is an Associate Attending Physician on the Breast Medicine Service at Memorial Sloan Kettering Cancer Center. She serves as the Vice Chair, Oncology Care for the Department of Medicine and Section Head of the Triple Negative Breast Cancer Clinical Research Program. She is Co-Chair of the MSK Outpatient Operations Committee and has served as the Clinical Director of the Breast Medicine Service. She is Associate Professor of Medicine at Weill Cornell Medicine in New York City. Her research program centers on the development of therapies for patients with breast cancer, with a particular focus on Triple Negative Breast Cancer and the role of the androgen receptor. Dr. Traina has served on numerous ASCO committees including the Scientific Program Committee for the ASCO Triple Negative Breast Cancer/Cytotoxics/Local Therapy track and she is past Chair for the ASCO Membership Committee 2020-2021 as well as the Co-Chair of the Breast Cancer Guidelines Advisory Group. Dr. Traina is a graduate of the 2016-2017 ASCO Leadership Development Program and the MSK Physician Executive Development Program. She is a founding member of the Translational Breast Cancer Research Consortium Triple Negative Breast Cancer Working Group. Her research efforts have led to many publications, peer-reviewed funding, and competitive funding. She has received recognition for her teaching from Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine and has been acknowledged with the Hally Yaccino Steiner Award from the Susan G. Komen Breast Cancer Foundation and the Hero Award from the Triple Negative Breast Cancer Foundation.



Stephen H. Wrzesinski, MD, PhD

Stephen H. Wrzesinski, MD, PhD, is Director of Immunooncology and Cell Therapies and a medical oncologist at New York Oncology Hematology (NYOH) as well as a Clinical Assistant Professor of Medicine at Albany Medical Center. Dr. Wrzesinski received his BA degree with a concentration in chemistry at Hamilton College followed by an MD and PhD in microbiology and immunology at SUNY Upstate Medical University in Syracuse, New York. His PhD research focused on the use of retroviral vectors to evaluate the biology and effects of the HTLV-1 tax gene expressed in human pleuripotential stem cells and neuroglial cells. He subsequently completed an internal medicine residency training program at Dartmouth Hitchcock Medical Center followed by a medical oncology fellowship at the Yale Cancer Center. During his residency training he was the recipient of a Hitchcock Foundation grant to evaluate genetic signatures of dendritic cell subtypes considered for future tumor vaccine studies. Dr. Wrzesinski received a Yale Melanoma SPORE Career Development Award during fellowship training to study immunotherapy combinations in preclinical melanoma models. He stayed on the Yale faculty as an

continued →

Assistant Clinical Professor of Medicine and transitioned to full clinical faculty with a focus on clinical research at the VA Medical Center in West Haven, Connecticut. During his tenure at Yale he published a number of articles detailing the role of TGF-beta in promoting tumorigenesis through immunosuppressive mechanisms within the tumor microenvironment and preliminary preclinical data suggesting a rationale of blocking this cytokine in combination with other immunotherapies such as IL-2 to promote antitumor immunity.

In 2011 Dr. Wrzesinski moved to the Capital District and joined the St. Peter's Cancer Care Center, becoming Division Chief of Medical Oncology/Hematology in 2015. During this time he opened a number of clinical trials as local PI, including two seminal studies evaluating the use of checkpoint inhibitor therapy to treat patients with advanced lung cancer: the CheckMate-153 and KEYNOTE-189 studies. He subsequently joined NYOH as Director of Immunooncology and Cell Therapy in 2019. Over the last two years he has opened clinical trials focusing on novel approaches to treat patients with melanoma and advanced lung cancer refractory to checkpoint inhibitor therapies. He has also overseen the early development of the immune effector cell therapy program at NYOH which has included the opening of the first outpatient-based CAR T trial in the Capital District in 2020 for patients with refractory B cell NHL (TRANSCEND-OUTREACH-007). He serves on a number of US Oncology Network clinical and research committees, including the Cellular and Gene Therapy Executive Committee. His clinical research interests focus on developing approaches for the treatment of patients with checkpoint inhibitor refractory malignancies as well as novel immune effector cell therapies in addition to CAR-T cell therapies to treat cancer. Dr. Wrzesinski subspecializes in cutaneous and thoracic oncology.

3rd Annual BREAST CANCER SYMPOSIUM

The Seasons of Breast Cancer

is supported by educational grants from:

**AstraZeneca | Daiichi Sankyo, Inc. | Novartis
Puma Biotechnology | Seagen, Inc.**

Thank you to our Product Theater Sponsors:

September 24, 2021 – 9:00am Eastern Daylight Time

The non-CME Ancillary Event titled:

Clinical Update on Extended Adjuvant Treatment for HER2+ Breast Cancer

is provided by:

Puma Biotechnology, Inc.

September 24, 2021 – 9:30am Eastern Daylight Time

The non-CME Ancillary Event titled:

Combining the HER2+ Breast Cancer Antibodies You Know in One Faster Mode of Administration

is provided by:

Genentech, Inc.

A Member of the Roche Group

September 24, 2021 – 1:00pm Eastern Daylight Time

The non-CME Ancillary Event titled:

Clinical Trial Evidence for a CDK4/6 Inhibitor Combination Therapy

Complemented by an Evaluation of Real-World Effectiveness

is provided by:

Pfizer Oncology

September 25, 2021 – 8:45am Eastern Daylight Time

The non-CME Ancillary Event titled:

A CDK 4 & 6 Inhibitor With Overall Survival Data for Women With HR+, HER2-

Metastatic Breast Cancer, Including Those Likely To Do Worse

is provided by:

Lilly USA, LLC

September 25, 2021 – 9:15am Eastern Daylight Time

The non-CME Ancillary Event titled:

TUKYSA® (tucatinib): Clinical Trial Data

is provided by:

Seagen, Inc.

September 26, 2021 – 9:30am Eastern Daylight Time

The non-CME Ancillary Event titled:

Learn More About an FDA-Approved Treatment for Metastatic Triple-Negative Breast Cancer

is provided by:

Gilead Sciences, Inc.

3rd Annual BREAST CANCER SYMPOSIUM

The Seasons of Breast Cancer

Thank you to our Sponsors and Exhibitors:

GOLD SPONSORSHIP:

AstraZeneca
Daiichi Sankyo, Inc.
Puma Biotechnology

SILVER SPONSORSHIP:

Genentech, Inc.
Gilead Sciences, Inc.
Lilly USA, LLC
Merck
Novartis
Pfizer, Inc.
Seagen, Inc.

BRONZE SPONSORSHIP:

Biotheranostics, Inc., a Hologic Company
NeoGenomics

PROUDLY HOSTED BY



World class cancer care. Close to home.

ACTIVITY PLANNED BY



3rd Annual BREAST CANCER SYMPOSIUM

The Seasons of Breast Cancer

Notes

This image shows a blank sheet of white paper with horizontal ruling lines. The lines are evenly spaced and extend across the width of the page. At the bottom of the page, there is a decorative border featuring a light blue wavy pattern. The overall appearance is that of a clean, unused piece of stationery or notebook paper.